Considering Artificial Intelligence and Machine Learning in Pharmaceutical Industries Research and Development

In the past decade, advancements in artificial intelligence (AI) and machine learning (ML) have revolutionized pharmaceutical research and development, powered by enhanced computational capabilities and data management. Deep learning techniques facilitate rapid analysis of extensive datasets, enabling the prediction and validation of peptide efficacy, critical for developing antimicrobial agents. AI excels at analyzing molecular structures to identify potential antibiotics, achieving over 85% success in early trials against resistant bacteria. Compared to traditional methods, AI accelerates drug development by 40–50% and cuts costs by approximately 35%, addressing the urgent threat of multidrugresistant bacteria that affect 700,000 individuals annually. Furthermore, AI models significantly enhance drug properties, including solubility and binding affinity, with 80–95% precision. Despite challenges with data consistency and model reliability, AI continues to reshape pharmaceutical innovation.